Cognitive functions and health-related quality of life in men with benign prostatic hyperplasia and symptoms of overactive bladder when treated with a combination of tamsulosin and solifenacin in a higher dosage

References

• Auffenberg GB, Helfand BT, McVary KT. Established medical therapy for benign prostatic hyperplasia. Urol Clin North Am. 2009;36:443–459.
   PubMed Web of Science ®Google Scholar
• Verhamme KM, Dieleman JP, Bleumink GS, et al. Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care – the Triumph project. Eur Urol. 2002;42:323–328.
   PubMed Web of Science ®Google Scholar
• Safarinejad MR. Prevalence of benign prostatic hyperplasia in a population-based study in Iranian men 40 years old or older. Int Urol Nephrol. 2008;40:921–931.
   PubMed Web of Science ®Google Scholar
• Loeb S, Kettermann A, Carter HB, et al. Prostate volume changes over time: results from the Baltimore Longitudinal Study of Aging. J Urol. 2009;182:1458–1462.
   PubMed Web of Science ®Google Scholar
• Bosch JL, Tilling K, Bohnen AM, et al. Establishing normal reference ranges for prostate volume change with age in the population-based Krimpen-study: prediction of future prostate volume in individual men. Prostate. 2007;67:1816–1824.
   PubMed Web of Science ®Google Scholar
• Arivazhagan J, Nandeesha H, Dorairajan LN, et al. Association of elevated interleukin-17 and angiopoietin-2 with prostate size in benign prostatic hyperplasia. Aging Male. 2017;20:115–118.
   PubMed Web of Science ®Google Scholar
• Ren H, Li X, Cheng G, et al. The effects of ROS in prostatic stromal cells under hypoxic environment. Aging Male. 2015;18:84–88.
   PubMed Web of Science ®Google Scholar
• Aktas BK, Gokkaya CS, Bulut S, et al. Impact of metabolic syndrome on erectile dysfunction and lower urinary tract symptoms in benign prostatic hyperplasia patients. Aging Male. 2011;14:48–52.
   PubMed Web of Science ®Google Scholar
• Besiroglu H, Dursun M, Otunctemur A, et al. The association between triglyceride high density lipoprotein cholesterol ratio and benign prostate hyperplasia in non-diabetic patients: a cross-sectional study. Aging Male. 2017;20:198–204.
   PubMed Web of Science ®Google Scholar
• Park SG, Yeo JK, Cho DY, et al. Impact of metabolic status on the association of serum vitamin D with hypogonadism and lower urinary tract symptoms/benign prostatic hyperplasia. Aging Male. 2017 [cited Apr 17]; [5 p.]. DOI:10.1080/13685538.2017.1311857
   PubMed Web of Science ®Google Scholar
• Kaplan SA, O’Neill E, Lowe R, et al. Prevalence of low testosterone in aging men with benign prostatic hyperplasia: data from the Proscar Long-term Efficacy and Safety Study (PLESS). Aging Male. 2013;16:48–51.
   PubMed Web of Science ®Google Scholar
• Kaplan SA, Lee JY, O’Neill EA, et al. Prevalence of low testosterone and its relationship to body mass index in older men with lower urinary tract symptoms associated with benign prostatic hyperplasia. Aging Male. 2013;16:169–172.
   PubMed Web of Science ®Google Scholar
• Singam P, Hong GE, Ho C, et al. Nocturia in patients with benign prostatic hyperplasia: evaluating the significance of ageing, co-morbid illnesses, lifestyle and medical therapy in treatment outcome in real life practice. Aging Male. 2015;18:112–117.
   PubMed Web of Science ®Google Scholar
• Ferreira FT, Daltoé L, Succi G, et al. Relation between glycemic levels and low tract urinary symptoms in elderly. Aging Male. 2015;18:34–37.
   PubMed Web of Science ®Google Scholar
• Roehrborn CG. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE. BJU Int. 2008;101:17–21.
   PubMed Web of Science ®Google Scholar
• Shahab N, Seki N, Takahashi R, et al. The profiles and patterns of detrusor overactivity and their association with overactive bladder symptoms in men with benign prostatic enlargement associated with detrusor overactivity. Neurourol Urodyn. 2009;28:953–958.
   PubMed Web of Science ®Google Scholar
• Hanuš T, Zámečník L, Doležal T, et al. Occurrence of overactive bladder in patients with benign prostatic hyperplasia in the Czech Republic. Urol Int. 2011;86:407–413.
   PubMed Web of Science ®Google Scholar
• Salah Azab S, Elsheikh MG. The impact of the bladder wall thickness on the outcome of the medical treatment using alpha-blocker of BPH patients with LUTS. Aging Male. 2015;18:89–92.
   PubMed Web of Science ®Google Scholar
• Bardoli AD, Taylor WSJ, Mahmalji W. Can the UroLift prostatic implant device treat the symptoms of benign prostatic hypertrophy, avoid sexual dysfunction and reduce hospital TURP waiting times? A single centre, single surgeon experience and review of the literature. Aging Male. 2017;20:192–197.
   PubMed Web of Science ®Google Scholar
• Yassin A, Nettleship JE, Talib RA, et al. Effects of testosterone replacement therapy withdrawal and re-treatment in hypogonadal elderly men upon obesity, voiding function and prostate safety parameters. Aging Male. 2016;19:64–69.
   PubMed Web of Science ®Google Scholar
• Allen S, Aghajanyan I. Use of thermobalancing therapy in ageing male with benign prostatic hyperplasia with a focus on etiology and pathophysiology. Aging Male. 2017;20:28–32.
   PubMed Web of Science ®Google Scholar
• Favilla V, Russo GI, Privitera S, et al. Impact of combination therapy 5-alpha reductase inhibitors (5-ARI) plus alpha-blockers (AB) on erectile dysfunction and decrease of libido in patients with LUTS/BPH: a systematic review with meta-analysis. Aging Male. 2016;19:175–181.
   PubMed Web of Science ®Google Scholar
• Ko WJ, Han HH, Ham WS, et al. Daily use of sildenafil 50mg at night effectively ameliorates nocturia in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: an exploratory multicenter, double-blind, randomized, placebo-controlled study. Aging Male. 2017;20:81–88.
   PubMed Web of Science ®Google Scholar
• Gong M, Dong W, Huang G, et al. Tamsulosin combined with solifenacin versus tamsulosin monotherapy for male lower urinary tract symptoms: a meta-analysis. Curr Med Res Opin. 2015;31:1781–1792.
   PubMed Web of Science ®Google Scholar
• Kosilov KV, Loparev SA, Ivanovskaya MA, et al. Additional correction of OAB symptoms by two anti-muscarinics for men over 50 years old with residual symptoms of moderate prostatic obstruction after treatment with Tamsulosin. Aging Male. 2015;18:44–48.
   PubMed Web of Science ®Google Scholar
• Kosilov KV, Loparev SA, Ivanovskaya MA, et al. Effectiveness of solifenacin and trospium for managing of severe symptoms of overactive bladder in patients with benign prostatic hyperplasia. Am J Mens Health. 2016;10:157–163.
   PubMed Web of Science ®Google Scholar
• Kosilov KV, Loparev SA, Ivanovskaya MA, et al. Comparative effectiveness of combined high-dosed Trospium and Solifenacin for severe OAB symptoms in age-related aspect. Int J Urol Nurs. 2015;9:108–113.
   Google Scholar
• Kosilov K, Loparev S, Kuzina I, et al. The effective tool for self-assessment of adherence to treatment in patients with benign prostatic obstruction and overactive bladder symptoms. Aging Male. 2017;20:1–6.
   Google Scholar
• Chancellor M, Boone T. Anticholinergics for overactive bladder therapy: central nervous system effects. CNS Neurosci Ther. 2012;18:167–174.
   PubMed Web of Science ®Google Scholar
• Tang DH, Colayco DC, Khalaf KM, et al. Impact of urinary incontinence on healthcare resource utilization, health-related quality of life and productivity in patients with overactive bladder. BJU Int. 2014;113:484–491.
   PubMed Web of Science ®Google Scholar